Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.42 |
| ▸ | CALCR | P30988 | 4/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CTSH | P09668 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | NMBR | P28336 | 2/20 | 0.40 |
| ▸ | GRPR | P30550 | 2/20 | 0.40 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29706215 | 0.78 | F2 (0.45) | F2CALCRPTPN1NTSR1 | |
| SCHEMBL29706189 | 0.77 | F2 (0.47) | F2CALCRCTSLCTSSCTSK | |
| SCHEMBL31362657 | 0.76 | NTSR2 (0.45) | F2PTPN1NTSR1 | |
| SCHEMBL30769519 | 0.76 | CTSL (0.41) | F2CTSLCTSSCTSKCTSH | |
| SCHEMBL29568610 | 0.75 | XIAP (0.47) | F2PTPN1NTSR1 | |
| SCHEMBL30933087 | 0.74 | APLNR (0.56) | F2CALCRHCRTR1HCRTR2CRHR1 | |
| SCHEMBL30769690 | 0.73 | CTSL (0.39) | F2CTSLCTSSCTSKCTSH | |
| SCHEMBL18891555 | 0.72 | F2 (0.46) | F2CTSLCTSSCTSKCTSH | |
| SCHEMBL30769779 | 0.72 | TRHR (0.37) | F2CTSLCTSSCTSKCTSH | |
| SCHEMBL29800934 | 0.72 | PTPN1 (0.42) | PTPN1NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | F2 3745/4885CALCR 4458/4885CTSL 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.